


PRODUCT INFORMATION



SR 11302

Item No. 16338

CAS Registry No.: 160162-42-5
Formal Name: (2E,4E,6Z,8E)-3-methyl-7-(4-methylphenyl)-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
MF: C₂₆H₃₂O₂
FW: 376.5
Purity: ≥95%
UV/Vis.: λ_{max}: 232, 360 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 year



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SR 11302 is supplied as a crystalline solid. A stock solution may be made by dissolving the SR 11302 in the solvent of choice, which should be purged with an inert gas. SR 11302 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of SR 11302 in these solvents is approximately 0.5, 10, and 20 mg/ml, respectively.

SR 11302 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SR 11302 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. SR 11302 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SR 11302 is a synthetic retinoid that inhibits AP-1 activity without activating transcription through RARE.¹ It significantly suppresses both AP-1 activation and phorbol ester-induced papilloma formation in mice when applied topically (0.1 μM).² SR 11302 is used to elucidate the role of AP-1 in various signaling pathways.^{3,4}

References

1. Fanjul, A., Dawson, M.I., Hobbs, P.D., *et al.* A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. *Nature* **372(6501)**, 107-111 (1994).
2. Huang, C., Ma, W.Y., Dawson, M.I., *et al.* Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. *Proc. Natl. Acad. Sci. USA* **94(11)**, 5826-5830 (1997).
3. Shiohara, M., Dawson, M.I., Hobbs, P.D., *et al.* Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. *Blood* **93(6)**, 2057-2066 (1999).
4. Kankaanranta, H., Ilmarinen, P., Zhang, X., *et al.* Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1. *PLoS One* **9(2)**, e90298 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM